News | March 10, 2026
Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
The first of four planned modules at the new plant is expected to come online by summer 2026
The first of four planned modules at the new plant is expected to come online by summer 2026
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Subscribe To Our Newsletter & Stay Updated
